PDA Training Course Extractables & Leachables

19-20 October 2023

Setting Up Leachable Studies: Do's and Don't's

Piet Christiaens

PDA
Parenteral Drug Association

Nelson Labs.
A Sotera Health company

CONNECTING
PEOPLE AND
SCIENCE AND
REGULATION®

USP <1664> - Why?

- Assess the potential toxic consequences = **safety**

- Assess impact on the **drug product quality**

- **"Real-time"** conditions

  - Storage time / temperature / humidity

  - Conditions similar to stability studies

  - Pharmaceutical formulation as contact solution

- The focus is on **quantification** of **"target"** compounds

  - Known polymer additives

  - Validation package of container suppliers

  - **Extractables** study information

- Quantitative aspect: **validated methods** (ICH Q2 (R1))

USP <1664> - Why?

Leachables studies can be used to:

- Facilitate **timely development** of the C/C packaging systems (material selection)

- Establish qual/quant **correlations** between **extractables & leachables**

- Establish **worst case DP leachables profiles**, allowing a safety evaluation on the leachable compounds

- Identify **trends in leachable accumulation** levels in the drug product over the shelf life

- Facilitate the **change control process**

- Facilitate **investigations into the origin of identified leachables** that potentially may cause OOS for a marketed drug product

USP <1664> - Why?

Formal leachables studies are especially relevant:

- With the **actual C/C-system** that will be commercialized
    - Final materials of construction (incl. color!)
    - Not with a prototype
    - Preferably on the same lots from the EXT study

- **On the product**, manufactured under conditions that reflect actual

  commercial processes of production
    - Fill & finishing & Sterilization
    - Distribution and storage
    - Clinical use

- During **late stage product development**
    - Simultaneous with the formal product stability assessment
    - Should be performed on the final drug product, not on simulations thereof

USP <1664> - Why?

- For **"high risk" dosage forms**
  - Pre-clinical stage: selection of packaging components (possible with placebo or simulant)
  - Leachable characterization is <u>recommended</u> for test article batches in **clinical studies** (phase III)
- **Post market, supports the change control**
  - Changes in formulation
  - Changes in the manufacturing process
  - Changes in primary & secondary packaging or changes in the MoC of components

USP <1664> - Why?

- Will depend upon the drug product

Examples of Packaging Concerns for Common Classes of Drug Products			
Degree of Concern Associated with the Route of Administration	Likelihood of Packaging Component-Dosage Form Interaction		
	High	Medium	Low
Highest	Inhalation Aerosols and Sprays	Injections and Injectable Suspensions; Inhalation Solutions	Sterile Powders and Powders for Injection; Inhalation Powders
High	Transdermal Ointments and Patches	Ophthalmic Solutions and Suspensions; Nasal Aerosols and Sprays	—
Low	Topical Solutions and Suspensions; Topical and Lingual Aerosols; Oral Solutions and Suspensions	—	Oral Tablets and Oral (Hard and Soft Gelatin) Capsules; Topical Powders; Oral Powders

USP <1664> - Why?

- Will **depend upon the purpose and goals** of a leachable study

- However, they require similar types of information

  – Chemical composition of packaging

  – Details of mfg. process

  – Extractables Assessment

  – ALL potential sources should be assessed

    • Primary packaging

    • Secondary packaging (important for semi-permeable containers)

- **Nature of contact** : direct versus indirect contact (migration mechanism)

- **Time of contact**: long term vs. transient

USP <1664> - Why?

- Characteristics of the drug product formulation

    – E.g. solid or liquid? (migration mechanism)

- Compounds that may migrate from process materials, may persist through the mfg. process and end up in the final DP: should be treated as leachables!!

Do − Don't #1: Blank solution

What is a good blank solution for leachables testing?

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?

• A good blank solution is the real drug product, but without leachables!!

Do − Don't #1: Blank solution

What do you want to test for?

What is a good blank solution for leachables testing?

Yes ✔	No ✖
Leachables from the container closure system	Drug impurities
	Filling line
	Manufacturing equipment
	Degradation products
	Batch variation

Do − Don't #1: Blank solution

What do you want to test for?

What is a good blank solution for leachables testing?

Yes ✅	No ❌
Leachables from the container closure system	Drug impurities
	Filling line
	Manufacturing equipment
	Degradation products
	Batch variation

A good blank solution is a leachables free drug product!!

Most important in the **screening step** in a LEACHABLE Study!

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?

WASHING LINE   TURN TABLE   LIQUID FILLING   CAPPING   TURN TABLE   INSPECTION TABLE   STICKER LABELLING

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?

WASHING LINE   TURN TABLE   LIQUID FILLING   CAPPING   TURN TABLE   INSPECTION TABLE   STICKER LABELLING

Collect contact samples here

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?

WASHING LINE   TURN TABLE   LIQUID FILLING   CAPPING   TURN TABLE   INSPECTION TABLE   STICKER LABELLING

Clean + inert

Collect blank solution here

Collect contact samples here

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?
- A good blank solution is a leachables free drug product!!

| WASHING LINE | TURN TABLE | LIQUID FILLING | CAPPING | TURN TABLE | INSPECTION TABLE | STICKER LABELLING |

- A good blank solution is best from the **same drug product batch** as the contact samples

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?
- A good blank solution is a leachables free drug product!!

WASHING LINE   TURN TABLE   LIQUID FILLING   CAPPING   TURN TABLE   INSPECTION TABLE   STICKER LABELLING

Contact samples

Blank solution

- A good blank solution is best from the **same drug product batch** as the contact samples
- A good blank solution is **put on controlled storage together with the contact samples**

Do – Don't #1: Blank solution

What is a good blank solution for leachables testing?

- A good blank solution is **a leachables free** drug product!!

- A good blank solution is from the **same drug product batch** as the contact samples

- A good blank solution is **put on controlled storage together with the contact samples**

Contact solution

AET

Blank solution

Do − Don't #1: Blank solution

What is a good blank solution for leachables testing?

- A good blank solution is **a leachables free** drug product!!

- A good blank solution is from the **same drug product batch** as the contact samples

- A good blank solution is **put on controlled storage together with the contact samples**

Contact solution

Blank solution

Do − Don't #1: Blank solution

Contact solution

Blank solution

Do – Don't #2: Batches?

- What the FDA wants....
  - Test multiple batches (3)

- What is a batch?
  - DP batch?
  - Batch of a CCS?
  - Batch of component of a CCS?
  - Batch of the raw material of a component of a CCS?

- Contact your supplier!

Do − Don't #3: Samples

- Sample requirements:
  - Provide sufficient amount of samples
    - Lab work has a large human factor => something can go wrong!
    - Spare samples can save the day!

  - Please don't overkill!!

Do – Don't #3: Samples

- Sample requirements:
  - Provide sufficient amount of samples
    - Lab work has a large human factor => something can go wrong!
    - Spare samples can save the day!

  - Please don't overkill!!
   - We optimize our capacity for controlled storage

Do – don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
  - Not only because PQRI and USP<1664> say so...

Do − don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
    - Not only because PQRI and USP<1664> say so…

Do − don't #4: Ageing program

- **Don't test your drug product only at the end of the shelf life**
  - Not only because PQRI and USP<1664> says so...

- **Design an ageing program for specific for your drug product:**
  - What is the shelf life?
  - What are the storage conditions?
  - What is the climatic zone of your market?

Do – don't #4: Ageing program

- **Don't test your drug product only at the end of the shelf life**
  - Not only because PQRI and USP<1664> says so...

- **Design an ageing program for specific for your drug product:**
  - What is the shelf life?
  - What are the storage conditions?
  - What is the climatic zone of your market?

- Example 1:
  - A product for Belgian market, shelf life = 36 months, storage at ambient temperature

Do − don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
  - Not only because PQRI and USP<1664> say so...

- Design an ageing program for specific for your drug product:
  - What is the shelf life?
  - What are the storage conditions?
  - What is the climatic zone of your market?
 - Are there specific in-use instructions for the patient?

- Example 1:
  - A product for Belgian market, shelflife = 36 months, storage at ambient temperature

|	0 months	1 month	3 months	6 months	12 months	18 months	24 months	30 months	36 months	… months
25 °C / 60 % RH	X			X	X	(X)	X		X	
30 °C / 65 % RH										
40 °C / 75 % RH	(X)		X	X						

Do – don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
  - Not only because PQRI and USP<1664> say so...

- Design an ageing program for specific for your drug product:
  - What is the shelf life?
  - What are the storage conditions?
  - What is the climatic zone of your market?
  - Are there specific in-use instructions for the patient?

- Example 2:
  - A product for Brazilian market, shelflife = 24 months, storage at ambient temperature

	0 months	1 month	3 months	6 months	12 months	18 months	24 months	30 months	36 months	… months
25 °C / 60 % RH										
30 °C / 65 % RH	X			X	X	X	X			
40 °C / 75 % RH	(X)		X	X						

Do – don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
  - Not only because PQRI and USP<1664> say so...

- Design an ageing program for specific for your drug product:
  - What is the shelf life?
  - What are the storage conditions?
  - What is the climatic zone of your market?
  - Are there specific in-use instructions for the patient?

- Example 3:
  - A product for Italian market, shelflife = 24 months, storage a 5 °C, in-use for max. 3 months at ambient temperature

	0 months	1 month	3 months	6 months	12 months	18 months	24 months	30 months	36 months	… months
5 °C	X			(X)	X	X	X			
25 °C / 60 % RH	(X)		(X)	X						

Do – don't #4: Ageing program

- Don't test your drug product only at the end of the shelf life
  – Not only because PQRI and USP<1664> say so...

- Design an ageing program for specific for your drug product:
  – What is the shelf life?
  – What are the storage conditions?
  – What is the climatic zone of your market?
  – Are there specific in-use instructions for the patient?

- Example 3:
  – A product for Italian market, shelflife = 24 months, storage a 5 °C, in-use for max. 3 months at ambient temperature

After x months ageing at 5°C, transfer the samples to 25 °C / 60 % RH to simulate the in-use period

	0 months	1 month	3 months	6 months	12 months	18 months	24 months	30 months	36 months	… months
5 °C	X			(X)	X	X	X			
25 °C / 60 % RH	(X)		(X)	X						

Do − don't #5: Quantitative methods

- How quantitative should the methods to measure the leachables be?
  - Is it always necessary to have fully validated, fully quantitative methods in place?

Do − don't #5: Quantitative methods

- How quantitative should the methods to measure the leachables be?   **No**

  - Is it always necessary to have fully validated, fully quantitative methods in place?

    - ICH Q2 R1 (Part I, chapter 1):
      "*The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose*"

Do – don't #5: Quantitative methods

- How quantitative should the methods to measure the leachables be? **No**

  - Is it always necessary to have fully validated, fully quantitative methods in place?

    - ICH Q2 R1 (Part I, chapter 1):
      "*The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose*"

  - Possibilities:

    - Fully validated method according to ICH Q2 R1 (Part II)
      - Complete (linear) method range
      - Known accuracy and precision

    - Limited validation (less parameters of ICH Q2 R1 taken in account)

    - Limit test

    - Method Suitability Test

Do − don't #5:
Quantitative methods

1,4-Dioxacyclotetradecane-5,14-dione - 9 Levels, 9 Levels Used, 9 Points, 9 Points Used, 6 QCs

$y = 1.364527 * x - 0.185074$
$R^2 = 0.99276780$
Type:Linear, Origin:Ignore, Weight:None

- Fully validated quantitative methods:

low accuracy, low precision

high accuracy, low precision

$\bullet$ = (accepted) true value, n = 6 (average)

low accuracy, high precision

high accuracy, high precision

Do − don't #5:
Quantitative methods

- Limited validated methods:

1,4-Dioxacyclotetradecane-5,14-dione - 9 Levels, 9 Levels Used, 9 Point
y = 1.364527 * x - 0.185074
R^2 = 0.99276780
Type:Linear, Origin:Ignore, Weight:None

low accuracy, low precision

high accuracy, low precision

● = (accepted) true value, n = 3 (average)

low accuracy, high precision

high accuracy, high precision

Do − don't #5:
## Quantitative methods

• Validated limit test:

1,4-Dioxacyclotetradecane-5,14-di...
y = 1.364527 * x - 0.185
R^2 = 0.99276780
Type:Linear, Origin:Igno

low accuracy, low precision

high accuracy, low precision

● = (accepted) true value, n = 6 (average)

low accuracy, high precision

high accuracy, high precision

Do − don't #5:
Quantitative methods

• Validated limit test:

1,4-Dioxacyclotetradecane-5,14-di...
y = 1.364527 * x - 0.185
R^2 = 0.99276780
Type:Linear, Origin:Ign...

low accuracy, low precision

high accuracy, low precision

● = (accepted) true value, n = 6 (average)

low accuracy, high precision

high accuracy, high precision

# Do − don't #5: Quantitative methods

- Method Suitability Test (MST)? = Cost Friendly and fast alternative to method development and validation
  - Spike analytical standards of the target compounds to a portion blank (leachables free) solution
    - N = 1
    - Spike level = AET
  - Spiked samples are treated as other samples
  - MST can prove the detectability of the targets with generic methods

Do − don't #5: Quantitative methods

Method Suitability Test (MST)

Drug matrix

Blank solution

Do – don't #5: Quantitative methods?

How quantitative should the methods to measure the leachables be?

- Is it always necessary to have fully validated, fully quantitative methods in place?
  - ICH Q2 R1 (Part I, chapter 1):
    "*The objective of validation of an analytical procedure is to demonstrate that it is suitable for its intended purpose*"

- **Possibilities:**
  - Fully validated method according to ICH Q2 R1 (Part II)
    - Complete (linear) method range
    - Known accuracy and precision
  - Limited validation (less parameters of ICH Q2 R1 taken in account)
  - Limit test
  - Method Suitability Test

- **What should you choose? It depends on**
  - Therapy (chronic vs short)
  - Drug product complexity
    - Chance on successful MST on complex drug matrices is rather low
  - Required sensitivity
  - Intended market (USA vs EU vs …)
  - Company policy

The flow of an E&L study: don't forget the screening step!!

EXT

TOX

LEA

TOX

Analyis of the drug product
Which chemical impurities are migrating into the drug product?
Leachables study

targeted

screening

+

Target compounds
Quantitative
Compound-specific tresholds

Unexpected leachables
Semi-Quantitative
Safety Concern Threshold / Qualification Threshold

KEEP IN MIND: FDA (D. Mellon) : All leachables in the DP at >5µg/day need to be identified
This implicitly calls for a screening step in a leachable evaluation

The flow of an E&L study:
don't forget the screening step!!

Screening for **Unexpected Leachables** is considered to be necessary
− when (technically) possible

Sources of those "unexpected leachables":
- Degradation of materials and additives over shelf life, not always accounted in an EXT study
- Degradation, hydrolysis / oxidation of Leachables when present in the DP
- Reactive leachables (reacting with DP ingredients or API)
- …

May address inaccuracies in the study design.

Technically possible *means: some DP are too complex in their composition too allow screening at final AET levels.*

Do − don't #6: Planning

- Plan ahead!
  - A leachables study design depends on
    - Extractables data
    - Method development and validation

Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
Extractables study	Feasibility or MD+ validation		LEA T0 months					
			LEA T 3 months					
				LEA T 6 months				
						LEA T 12 months		

Do – don't #7:
Simulation study vs. Leachables study

- **Differences with a leachables studies**

  – The drug product is replaced with a simulating solvent

  – The ageing conditions have been accelerated

  – The test article can be the complete packaging system or a partial packaging system

- **Purpose according to USP<1663>**

  – Find + identify extractables which are probable leachables

  – Establish which extractables must be targeted in a migration study

    - Screening

    - Mimic circumstances of final drug product: acceleration, moderate exaggeration

    - Worst case: sufficient amounts to identify

    - Safety/ toxicological risk assessment to define target leachables

Do – don't #7:
Simulation study vs. Leachables study

How to select a simulating solvent?

1. Aqueous based solutions with organic solvent added to mimic the extraction propensity of the actual DP

   – Mix of alcohol in water

     • Nelson Labs Whitepaper (www.nelsonlabs.com)

   > **WHITEPAPER**
   > ## Establishing the Proper Alcohol/Water Proportion for Simulating Solvents Used in Controlled Extraction Studies
   >
   > **March 25, 2019** | By: Dennis Jenke
   >
   > The purpose of this paper is to provide guidance on determining the proper alcohol/water proportion for simulating solvents used in controlled extraction studies relevant to drug products that are packaged in plastic container systems, administered via plastic devices or manufactured using systems that consist of plastic components.

2. The drug product vehicle

   – When the DPV is not substantially different from the DP

3. The Drug Product itself

   – "Screening leachable study"

Do − don't #7:
Simulation study vs. Leachables study

How to select the conditions of a simulation study

1. *Exaggerated and accelerated* conditions

    – Exaggerated:

    - Composition of the simulant

    - Increased surface area

    - Underfilling (bags)

    – Accelerated: temperature of storage − accelerated ageing

2. Study the *complete packaging system*, not only the individual parts

3. Or *study some parts of the packaging system* which are of particular interest

Remark: *beware of solubility of the extractables in the extraction medium when "back extrapolating" to original ratios*

Only for visualisation − rubber plunger surface area to solution >> 10

novo nordisk®

Do – don't #7:
Simulation study vs. Leachables study

- Regulatory acceptance of a simulation study – **think as a regulator**

- **Example 1**: use a simulant of 50 % ethanol in water

  – Justifications will need to be provided to prove the predictive character of a simulation study.

  – Secondary leachables – reaction products of leachables with DP – are not covered

- CONCLUSION: Risky!

  - The approach can be taken if a drug formulation is extremely complex and no trace analysis is possible. However, the failed attempts should be documented to help justifying the alternative approach

Do – don't #7:
Simulation study vs. Leachables study

- Regulatory acceptance of a simulation study – **think as a regulator**

  – Justifications will need to be provided to prove the predictive character of a simulation study compared to a formal leachables study.

  – Only the end point is tested, no trend analysis possible

- CONCLUSION: contributes to the E&L assessment, but this is not sufficient!

Do − don't #8:
What if the formulation is too complex?

What if the DP is so complex and challenging in its formulation that a normal analytical approach cannot be taken?

- Try to prove and document the analytical difficulties

- Narrow down the analytics

    – Very targeted, specific compound detection

    – No screening possible

- Consider a simulation study

    – **Justify a simulation study by proving the difficulties in the regular leachable study approach**